Doripenem: A new addition to the carbapanem class of antimicrobials

Recent Patents on Anti-Infective Drug Discovery

Volumn 4, Issue 1, 2009, Pages 18-28

  Schafer, Jason J ^a   Goff, Debra A ^b   Mangino, Julie E ^b  

^a St Margaret Memorial Hospital   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Carbapenem; Doripenem; Multi drug resistant; Pharmacodynamics; Pseudomonas

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VALPROIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER; ADD ON THERAPY; ADJUVANT THERAPY; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; APPENDICITIS; BACTEREMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TOLERABILITY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PERITONITIS; PHARMACODYNAMICS; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PYELONEPHRITIS; REVIEW; SEIZURE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; ANTIBIOTIC RESISTANCE; CROSS INFECTION; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, VENTILATOR-ASSOCIATED; URINARY TRACT INFECTIONS;

EID: 62749157619     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489109787236283     Document Type: Review

References (65)

1. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Richard PW. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 1-11.
2. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report data summary from Jan 1992 through June 2004, issued Oct 2004. Am J Infect Control 2004; 32: 470-485.
3. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant Gram-negative bacilli in North America: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2008; 28: 235-249.
4. Livermore DM, Russell Hope, Brick G, Lillie M, Reynolds R. On behalf of the BSAC working parties on resistance surveillance. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62: ii41-ii54.
5. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2): S82-S89.
6. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001; 29(Suppl 4): N114-120.
7. Giske CG, Moneet DL, Cars O, Carmeli Y. On behalf of react-action on antibiotic resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52: 813-821.
8. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-126.
9. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36: 1089-1096.
10. Malafia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections. In: Program and Abstracts of the 46th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington DC. Am Society of Microbiol 2006; L-1564b.
11. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A Phase III, prospective, multicenter, randomized, double-blind, non-inferiority study. Clin Ther 2008; 30: 868-883.
12. Naber K, Redman R, Kotey P, et al. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infection and pyelonephritis. In: Program and abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases. Munich, Germany 2007.
13. Doribax (Doripenem) Package Information. Ortho-McNeil 2007.
14. Tewari, N., Meeran, H., Rai, B., George, V.: WO2006117763A2 (2006).
15. Tewari, N., George, V., Mane, A., Meeran, H.N.P.N., Prasad, M.: W02007029084A2 (2007).
16. Meeran, H.N.P.N., Rai, B.P., Singh, S.K., Prasad, M.: US2007037971A1 ( 2007).
17. Blizzard, T.A., Chen, H.Y., Wu, J.Y., Kim, S., Ha, S., Mortko, C.J., Variankaval, N., Chiu, A.: WO2008039420A2 (2008).
18. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analysis to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005; 49: 3944-3947.
19. Kim A, Banevicius MA, Nicolau DP. in vivo Pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008; 52: 2497-2502.
20. Sumitani Y, Kobayashi Y. Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetic and pharma-codynamics theory. Jpn J Antibiot 2007; 60: 394-403
21. Nicolau DP. Carbapenems: A potent class of antibiotics. Expert Opin Pharmacother 2008; 9: 23-37.
22. Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin Invest Drugs 2002; 11: 529-44.
23. Primaxin (Imipenem-cilastatin) Package Information. Merck 2007.
24. Merrem (Meropenem) Package Information. Astra-Zeneca 2008.
25. Invanz (Ertapenem) Package Information. Merck 2008.
26. Davies TA, Shang W, Bush K, Flamm RK. Activity of doripenem and comparators to penicillin-binding proteins in Eshcherichia coli and Pseudomonas aeruginosa. Antimicrob Agents and Chemother 2008; ahead of print.
27. Davies TA, Shang W, Bush K, Flamm RK. Activity of doripenem and comparator β-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in penicillin binding domains of pbp1a, pbp2b, and pbp 2x. J Antimicrob Chemother 2008; 61: 751-753.
28. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin Microbiol Infect 2005; 11: 974-984.
29. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54: 144-154.
30. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. in vitro Activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother 2008; 52: 761-766.
31. Wexler HM, Engel AE, Glass D, Li C. in vitro Activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005; 49: 4413-4417.
32. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004; 48: 1313-1319.
33. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. Diag Micro Infect Dis 2005; 52: 71-74.
34. Chen Y, Garber E, Zhao Q,et al. in vitro Activity of doripenem (S-4661) against multidrug-resistant gram-negative Bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2510-2511.
35. Traczewski MM, Brown SD. in vitro Activity of doripenem against Pseudomonas aeruginosa and Burkolderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50: 819-821.
36. Pillar CM, Torres MK, Brown NP, Dineshchandra S, Sahm DF. in vitro Activity of doripenem, a carbapenem for the treatment of challenging gram negative infections, against recent US clinical isolates. Antimicrob Agents Chemother 2008 [Ahead of print].
37. Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlosky JA. in vitro Antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48: 1384-1396.
38. Nomora S, Nagayama A. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patient with complicated urinary tract infections. J Chemother 2002; 14: 155-160
39. Watanabe A, Takahashi H, Kikuchi T, et al. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy 2000; 46: 184-187.
40. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. in vitro and in vivo Antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42: 94-99.
41. Livermore DM. Of Pseudomonas porins pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-250.
42. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006; 34: S20-28.
43. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: Respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43: 424- 427.
44. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 413-420.
45. Patterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-686.
46. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXYOprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-3327.
47. Frische TR, Sader HS, Toleman MA, et al. Emerging metallo-beta-lactamase-mediated resistances: A summary report from the worldwide SENTRY antimicrobial surveillance program. Clin Infect Dis 2005; (Suppl 41): S276-278.
48. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-3092.
49. Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: The high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 2006; 59: 220-228.
50. Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006; 55: 241 -243.
51. Chikauchi, K., Ida, M., Abe, T., Hiraiwa, Y., Morinaka, A., Kudo, T.: EP1941873A1 (2008).
52. Chikauchi, K., Ida, M., Abe, T., Hiraiwa, Y., Morinaka, A., Kudo, T.: US20080090825A1 (2008).
53. Andes DR, Kiem S, Craig WA. in vivo Pharmacodynamic activity of a new carbapenem, doripenem, against multiple bacteria in a murine thigh infection model. In: Program and Abstracts of the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington DC. American Society of Microbiology 2003.
54. Lodise TP, Lomaestro BM, Drusano GL. Society of infectious diseases pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insight from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26: 1320-1332.
55. Deryke CA, Lee SY, Kuti JL, Nicolau DP. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles: Impact on the development of resistance. Drugs 2006; 66: 1-14.
56. Psathas PA, Gilmor T, Schaufelberger D, Ikeda K, Nageo K. Stability of high and low concentrations of doripenem (500mg) for injection in representative infusion fluids and containers. In: Program and abstracts of the American Society of Health System Pharmacists Summer Meeting and Exhibition, Seattle, Washington 2008.
57. Cirillo I, Mannens G, Janssen C, et al. The disposition, metabolism, and excretion of 14C-doripenem after a single 500mg intravenous infusion in healthy men. Antimicrob Agents Chemother 2008; 52: 3478-383.
58. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T. Pharmacodynamic assessment of doripenem in peritoneal fluid against gram-negative organisms: Use of pharmacokinetic modeling and Monte Carlo simulation. Diagn Microbiol Infect Dis 2008 (in press).
59. Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 2007; 60: 1395-1397.
60. Clinicaltrials.gov RCT register: NCT00589693.
61. Horiuchi M, Kimura M, Tokumura M, et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006; 222: 114-124.
62. Koppel BS, Hauser WA, Politis C, van Duin D, Daras M. Seizures in the critically ill: The role of imipenem. Epilepsia 2001; 42: 1590-1593.
63. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin. Am J Med 1988; 84: 911-918.
64. Nakagima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproric acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004; 32: 1383-91.
65. Kajita, S.: EP1956027A1 (2008).